[1]刘天琪,张秀英,纪立农.促甲状腺激素受体抗体的检测及应用进展[J].国际内分泌代谢杂志,2021,41(01):5-9.[doi:10.3760/cma.j.cn121383-20200608-06021]
 Liu Tianqi,Zhang Xiuying,Ji Linong..Progression of assay and clinical practice of thyroid stimulating hormone receptor antibody[J].International Journal of Endocrinology and Metabolism,2021,41(01):5-9.[doi:10.3760/cma.j.cn121383-20200608-06021]
点击复制

促甲状腺激素受体抗体的检测及应用进展()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年01期
页码:
5-9
栏目:
甲状腺疾病专题
出版日期:
2021-01-20

文章信息/Info

Title:
Progression of assay and clinical practice of thyroid stimulating hormone receptor antibody
作者:
刘天琪张秀英纪立农
北京大学人民医院内分泌科 100044
Author(s):
Liu Tianqi Zhang Xiuying Ji Linong.
Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing 100044, China
关键词:
促甲状腺激素受体抗体 Graves病 甲状腺功能亢进症 甲状腺相关眼病
Keywords:
Thyroid Stimulating hormone receptor antibody Graves' disease Hyperthyroidism Graves' orbitopathy
DOI:
10.3760/cma.j.cn121383-20200608-06021
摘要:
促甲状腺激素(thyroid stimulating hormone,TSH)受体抗体(TSH receptor antibody,TRAb)在自身免疫性甲状腺病患者体内特异性存在,其中甲状腺刺激性抗体(thyroid stimulating antibody,TSAb)/TSI受体刺激性免疫球蛋白(TSI)被认为是Graves病(Graves' disease,GD)的致病因素。TRAb的检测技术不断更新,新一代针对特异性TSI的检测方法正逐步应用于临床。TRAb尤其是TSI不仅对GD和Graves眼病的诊断、治疗及预后评估有重要的意义,对妊娠期甲状腺功能亢进症的治疗以及新生儿甲状腺功能异常的风险评估也具有重要价值。
Abstract:
Thyroid stimulating hormone(TSH)receptor antibody(TRAb)exists specifically in patients with autoimmune thyroid disease. Thyroid stimulating antibody(TSAb)/TSHR stimulating immunoglobulin(TSI)is considered to be the pathogenic antibody of Graves' disease(GD). The methods and technologies of measuring TRAb are constantly being explored and updated, with a new generation assay of TSI is gradually being applied in the clinical practice. TRAb, especially TSI, not only has important clinical significance for the diagnosis, treatment and prognostic evaluation of GD and Graves' orbitopathy, but also has important guiding value in the treatment of hyperthyroidism during pregnancy and the risk assessment of fetal thyroid dysfunction.

参考文献/References:

[1] Hesarghatta Shyamasunder A,Abraham P. Measuring TSH receptor antibody to influence treatment choices in Graves' disease[J].Clin Endocrinol(Oxf),2017,86(5):652-657.DOI:10.1111/cen.13327.
[2] Ross DS,Burch HB,Cooper DS,et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J].Thyroid,2016,26(10):1343-1421.DOI:10.1089/thy.2016.0229.
[3] Kotwal A,Stan M. Thyrotropin receptor antibodies-an overview[J].Ophthalmic Plast Reconstr Surg,2018,34(4S Suppl 1):S20-S27.DOI:10.1097/iop.0000000000001052.
[4] Smith TJ,Hegedüs L. Graves' disease[J].N Engl J Med,2016,375(16):1552-1565.DOI:10.1056/NEJMra1510030.
[5] Neumann S,Place RF,Krieger CC,et al. Future prospects for the treatment of Graves' hyperthyroidism and eye disease[J].Horm Metab Res,2015,47(10):789-796.DOI:10.1055/s-0035-1555901.
[6] Sanders J,Jeffreys J,Depraetere H,et al. Thyroid-stimulating monoclonal antibodies[J].Thyroid,2002,12(12):1043-1050.DOI:10.1089/105072502321085135.
[7] Doroudian S,Pedersen IB,Knudsen CS,et al. Comparison of three competitive immunoassays for measurement of TSH receptor antibodies in patients with Graves' disease[J].Scand J Clin Lab Invest,2017,77(7):535-540.DOI:10.1080/00365513.2017.1354257.
[8] Tozzoli R,Bagnasco M,Giavarina D,et al. TSH receptor autoantibody immunoassay in patients with Graves' disease:improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis[J].Autoimmun Rev,2012,12(2):107-113.DOI:10.1016/j.autrev.2012.07.003.
[9] Araki N,Iida M,Amino N,et al. Rapid bioassay for detection of thyroid-stimulating antibodies using cyclic adenosine monophosphate-gated calcium channel and aequorin[J].Eur Thyroid J,2015,4(1):14-19.DOI:10.1159/000371740.
[10] Frank CU,Braeth S,Dietrich JW,et al. Bridge technology with TSH receptor Chimera for sensitive direct detection of TSH receptor antibodies causing Graves' disease:analytical and clinical evaluation[J].Horm Metab Res,2015,47(12):880-888.DOI:10.1055/s-0035-1554662.
[11] Cheng XQ,Chai XF,Ma CC,et al. Clinical diagnostic performance of a fully automated TSI immunoassay vs. that of an automated antiTSHR immunoassay for Graves' disease:a Chinese multicenter study[J].Endocrine,2020.DOI:10.1007/s12020-020-02386-2.
[12] Bell L,Hunter AL,Kyriacou A,et al. Clinical diagnosis of Graves' or non-Graves' hyperthyroidism compared to TSH receptor antibody test[J].Endocr Connect,2018,7(4):504-510.DOI:10.1530/ec-18-0082.
[13] Mckee A,Peyerl F. TSI assay utilization:impact on costs of Graves' hyperthyroidism diagnosis[J].Am J Manag Care,2012,18(1):e1-14.
[14] Kim JJ,Jeong SH,Kim B,et al. Analytical and clinical performance of newly developed immunoassay for detecting thyroid-stimulating immunoglobulin,the Immulite TSI assay[J].Scand J Clin Lab Invest,2019,79(6):443-448.DOI:10.1080/00365513.2019.1658216.
[15] Allelein S,Ehlers M,Goretzki S,et al. Clinical evaluation of the first automated assay for the detection of stimulating TSH receptor autoantibodies[J].Horm Metab Res,2016,48(12):795-801.DOI:10.1055/s-0042-121012.
[16] Laurberg P,Wallin G,Tallstedt L,et al. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs,surgery,or radioiodine:a 5-year prospective randomized study[J].Eur J Endocrinol,2008,158(1):69-75.DOI:10.1530/eje-07-0450.
[17] Carella C,Mazziotti G,Sorvillo F,et al. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before,at the end of methimazole treatment,and after drug withdrawal:evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period[J].Thyroid,2006,16(3):295-302.DOI:10.1089/thy.2006.16.295.
[18] Kahaly G J,Diana T,Kanitz M,et al. Prospective trial of functional thyrotropin receptor antibodies in Grave's disease[J].J Clin Endocrinol Metab,2020,105(4):e1006-1014.DOI:10.1210/clinem/dgz292.
[19] Hwang S,Shin DY,Song MK,et al. High cut-off value of a chimeric TSH receptor(Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months[J].Endocrine,2015,48(1):89-95.DOI:10.1007/s12020-014-0325-8.
[20] Rosenberg Bezalel S,Elbirt D,Leiba H,et al. Graves' opthalmopathy[J].Isr Med Assoc J,2017,19(3):188-192.
[21] Seo S,Sánchez Robledo M. Usefulness of TSH receptor antibodies as biomarkers for Graves' ophthalmopathy:a systematic review[J].J Endocrinol Invest,2018,41(12):1457-1468.DOI:10.1007/s40618-018-0945-6.
[22] Roos JCP,Paulpandian V,Murthy R. Serial TSH-receptor antibody levels to guide the management of thyroid eye disease:the impact of smoking,immunosuppression,radio-iodine,and thyroidectomy[J].Eye(Lond),2019,33(2):212-217.DOI:10.1038/s41433-018-0242-9.
[23] Woo YJ,Jang SY,Lim TH,et al. Clinical association of thyroid stimulating hormone receptor antibody levels with disease severity in the chronic inactive stage of Graves' orbitopathy[J].Korean J Ophthalmol,2015,29(4):213-219.DOI:10.3341/kjo.2015.29.4.213.
[24] Jang SY,Shin DY,Lee EJ,et al. Correlation between TSH receptor antibody assays and clinical manifestations of Graves' orbitopathy[J].Yonsei Med J,2013,54(4):1033-1039.DOI:10.3349/ymj.2013.54.4.1033.
[25] Li Y,Xu T,Mo Q,et al. Thyrotropin receptor antibody:a novel risk indicator for pregnancy loss[J].Clin Biochem,2019,64:44-48.DOI:10.1016/j.clinbiochem.2018.11.017.
[26] Alexander EK,Pearce EN,Brent GA,et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum[J].Thyroid,2017,27(3):315-389.DOI:10.1089/thy.2016.0457.
[27] Abeillon-Du Payrat J,Chikh K,Bossard N,et al. Predictive value of maternal second-generation thyroid-binding inhibitory immunoglobulin assay for neonatal autoimmune hyperthyroidism[J].Eur J Endocrinol,2014,171(4):451-460.DOI:10.1530/eje-14-0254.
[28] Peleg D,Cada S,Peleg A,et al. The relationship between maternal serum thyroid-stimulating immunoglobulin and fetal and neonatal thyrotoxicosis[J].Obstet Gynecol,2002,99(6):1040-1043.DOI:10.1016/s0029-7844(02)01961-0.
[29] Ide A,Amino N,Nishihara E,et al. Partial prediction of postpartum Graves' thyrotoxicosis by sensitive bioassay for thyroid-stimulating antibody measured in early pregnancy[J].Endocr J,2016,63(10):929-932.DOI:10.1507/endocrj.EJ16-0296.

相似文献/References:

[1]陈宁,朱云娟,陈慧,等.TSHR胞外区中间段在BALB/c小鼠体内的免疫原性研究[J].国际内分泌代谢杂志,2007,(04):267.
[2]贾媛媛,陈莉丽.Th17细胞与Graves病及桥本甲状腺炎[J].国际内分泌代谢杂志,2014,(05):344.[doi:10.3760/cma.j.issn.1673-4157.2014.05.016]
 Jia Yuanyuan,Chen Lili.Relationship between Th17 cells and Graves' disease,Hashimoto's thyroiditis[J].International Journal of Endocrinology and Metabolism,2014,(01):344.[doi:10.3760/cma.j.issn.1673-4157.2014.05.016]
[3]房方,卫红艳,王坤玲,等.硒治疗自身免疫性甲状腺疾病的荟萃分析[J].国际内分泌代谢杂志,2016,36(04):247.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
 Fang Fang,Wei Hongyan,Wang Kunling,et al.A meta-analysis of selenium in the treatment of autoimmune thyroid diseases[J].International Journal of Endocrinology and Metabolism,2016,36(01):247.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
[4]郑仁东,刘超.白细胞介素-6与甲状腺疾病[J].国际内分泌代谢杂志,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
 Zheng Rendong,Liu Chao.Interleukin-6 and thyroid disease[J].International Journal of Endocrinology and Metabolism,2016,36(01):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
[5]郑慧娟,魏璠,魏军平.自噬与自身免疫性甲状腺疾病[J].国际内分泌代谢杂志,2017,37(01):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
 Zheng Huijuan,Wei Fan,Wei Junping..Autophagy and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2017,37(01):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
[6]韩煦,魏军平.促甲状腺激素受体抗体的检测及其在Graves病 诊疗中的价值[J].国际内分泌代谢杂志,2017,37(02):94.[doi:10.3760/cma.j.issn.1673-4157.2017.02.006]
 Han Xu,Wei Junping..Thyroid stimulating hormone receptor antibodies assays and its clinical significance in Graves' disease[J].International Journal of Endocrinology and Metabolism,2017,37(01):94.[doi:10.3760/cma.j.issn.1673-4157.2017.02.006]
[7]黄慧 胡欣 徐一娇 刘超.利妥昔单克隆抗体治疗Graves病的作用机制[J].国际内分泌代谢杂志,2018,38(02):121.[doi:10.3760/cma.j.issn.1673-4157.2018.02.013]
 Huang Hui,Hu Xin,Xu Yijiao,et al.Mechanism of rituximab in the treatment of Graves' disease[J].International Journal of Endocrinology and Metabolism,2018,38(01):121.[doi:10.3760/cma.j.issn.1673-4157.2018.02.013]
[8]苏亚峰 相萍萍 陈国芳 刘超.碘治疗Graves病的研究进展[J].国际内分泌代谢杂志,2019,39(01):21.[doi:10.3760/cma.j.issn.1673-4157.2019.01.005]
 Su Yafeng,Xiang Pingping,Chen Guofang,et al.Research progress of iodine in treating Graves' disease[J].International Journal of Endocrinology and Metabolism,2019,39(01):21.[doi:10.3760/cma.j.issn.1673-4157.2019.01.005]
[9]赫晓晴 单忠艳.肠道菌群与自身免疫性甲状腺疾病[J].国际内分泌代谢杂志,2020,40(03):179.[doi:10.3760/cma.j.issn.1673-4157.2020.03.008]
 He Xiaoqing,Shan Zhongyan.Gut microbiota and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2020,40(01):179.[doi:10.3760/cma.j.issn.1673-4157.2020.03.008]
[10]龙丽 张秀英 纪立农.甲状腺相关眼病治疗新希望——IGF-Ⅰ受体拮抗剂[J].国际内分泌代谢杂志,2022,42(04):256.[doi:10.3760/cma.j.cn121383-20210420-04055]
 Long Li,Zhang Xiuying,Ji Linong..New hope for the treatment of thyroid associated orbitopathy-IGF-Ⅰ receptor antagonist[J].International Journal of Endocrinology and Metabolism,2022,42(01):256.[doi:10.3760/cma.j.cn121383-20210420-04055]

备注/Memo

备注/Memo:
通信作者:张秀英,Email:zhangxiuying717@163.com
更新日期/Last Update: 2021-01-20